Education
About Us
Working with TipRanks
Follow Us
Co-Diagnostics Inc (CODX)
NASDAQ:CODX
CODX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.28 - $2.23
Previous CloseN/A
Volume146.43K
Average Volume (3M)269.61K
Market Cap
$10.74M
Enterprise Value-$2.81M
Total Cash (Recent Filing)-$33.80K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.63
Next Earnings
May 08, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding33,572,643
10 Day Avg. Volume392,991
30 Day Avg. Volume269,607
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.01
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.96
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$1.00Price Target Upside222.58% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Co-Diagnostics News
PremiumCompany Announcements
Co-Diagnostics Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Co-Diagnostics Reports 2024 Financial Results and Strategic Progress
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNet loss was $9.7M, lower than the estimated loss of $10.6M.
Manufacturing ExpansionThe company has inaugurated a new manufacturing facility in South Salt Lake to manufacture its patented Co-Primers oligonucleotides, the Co-Dx PCR Pro instrument, and test cups for the new Co-Dx PCR platform.
Regulatory ClearanceThe company plans to submit a new iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance, which could enhance the test and streamline operational and manufacturing processes.
Bears Say
Price Objective DecreaseThe price objective decreased to $1 due to a higher number of shares outstanding and a lower cash position.
Regulatory ChallengesThe company withdrew its 510(k) application for its Co-Dx PCR COVID-19 test due to concerns about shelf-life stability.
Revenue DeclineRevenue for the full year 2024 was $3.9M, representing a 43% year-over-year decline.
---
Ownership Overview
5.09% Insiders
7.38% Mutual Funds
5.09% Other Institutional Investors
76.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CODX FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was $0.28 and its highest was $2.23 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is $10.74M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is May 08, 2025 which is in 37 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Mar 27, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.02.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -0.33.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 33,572,643 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -17.949%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in CODX
---
Co-Diagnostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (222.58% Upside)
$1.00 (222.58% Upside)
Hedge Fund Trend
Decreased
By 36.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.42%
12-Months-Change
Fundamentals
Return on Equity
-53.65%
Trailing 12-Months
Asset Growth
-31.31%
Trailing 12-Months
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
---
CODX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in the Co-Dx PCR platform and test pipeline, supported by external organizations, and new manufacturing capabilities. However, financial challenges were evident with decreased revenue and increased legal expenses, along with a setback in regulatory progress for the COVID-19 test.Read More>---
CODX Stock 12 Month Forecast
Average Price Target
$1.00
▲(222.58% Upside)
Technical Analysis
---